Skip to main content
DeutschDE
European Commission logo print header

Innovative anti-influenza drugs excluding viral escape

Ziel

ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel
concept that precludes the development of viral resistance and ensures efficacy against
upcoming pandemic influenza strains. Viral replication is known to depend on multiple host
factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will
aim at drugs interfering with host-response pathways. The concept of drugs targeting human
factors, established in treatment of other diseases, has yet not been sufficiently explored for
treatment of viral infections, although it bears compelling advantages over conventional
antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage
against unprecedented viral variants.
ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment
and prevention options against seasonal and pandemic influenza virus infections. By building
upon an existing panel of potent human targets and firm knowledge derived from FP6 project
RIGHT, an interdisciplinary consortium will pursue the identification and validation of small
molecule ligands and inhibitory RNA molecules effective against influenza infection.
Promising modulators will form the basis to generate lead molecules that will be further
refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing
proof of concept in animal models, safety and toxicology profiles. They will allow initiating
complete clinical trials immediately after the phase of FP7 support, thanks to the commitment
already taken by investors from the private sector. The consortium includes several SMEs,
internationally renowned research groups and clinical institutions with extensive experience
in anti-influenza treatment and clinical trials. An already agreed common exploitation model
will provide a smooth route to market and optimal use of the project results.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP7-INFLUENZA-2010
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
EU-Beitrag
€ 1 448 954,00
Adresse
HOFGARTENSTRASSE 8
80539 Munchen
Deutschland

Auf der Karte ansehen
Region
Bayern Oberbayern München, Kreisfreie Stadt
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Birgit Gieding (Ms.)
Links
Gesamtkosten
Keine Daten

Beteiligte (10)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 26 Mai 2017

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/259842/de

European Union, 2024